Document Detail


CDKs and CKIs: molecular targets for tissue remodelling.
MedLine Citation:
PMID:  12402499     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Effective tissue remodelling is essential to the survival of adult organs. Many of the signalling pathways that control these cellular decisions are regulated by nuclear interactions of cell-cycle proteins. Molecules that target cyclin-dependent kinases (CDKs) or CDK inhibitors (CKIs) represent a new class of therapeutic agents that influence tissue remodelling in several organ systems. An understanding of their cell-specific functions is leading to the development of exciting and bold approaches to the treatment cancer, cardiovascular disease and other diseases.
Authors:
Elizabeth G Nabel
Related Documents :
11216479 - Antitumor protein (ap) from a mushroom induced apoptosis to transformed human keratinoc...
17714589 - P21 is decreased in polycystic kidney disease and leads to increased epithelial cell cy...
9627219 - Histone h3 phosphorylation and expression of cyclins a and b1 measured in individual ce...
19001089 - Nucleus-specific and cell cycle-regulated degradation of mitogen-activated protein kina...
12718939 - Age-related changes in mature cd4+ t cells: cell cycle analysis.
11982759 - Ultraviolet-b-induced g1 arrest is mediated by downregulation of cyclin-dependent kinas...
23143599 - Vertebrate kidney tubules elongate using a planar cell polarity-dependent, rosette-base...
24520299 - Effects of the myeloid cell nuclear differentiation antigen on the proliferation, apopt...
23728309 - Measuring intracellular ca2+ changes in human sperm using four techniques: conventional...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Nature reviews. Drug discovery     Volume:  1     ISSN:  1474-1776     ISO Abbreviation:  Nat Rev Drug Discov     Publication Date:  2002 Aug 
Date Detail:
Created Date:  2002-10-29     Completed Date:  2002-12-03     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  101124171     Medline TA:  Nat Rev Drug Discov     Country:  England    
Other Details:
Languages:  eng     Pagination:  587-98     Citation Subset:  IM    
Affiliation:
Cardiovascular Branch, National Heart, Lung and Blood Institute/National Institutes of Health, Building 10/8C103, 10 Center Drive, Bethesda, Maryland 20892, USA. enabel@nih.gov
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Cyclin-Dependent Kinases / antagonists & inhibitors*,  metabolism
Cyclins / antagonists & inhibitors,  metabolism
Drug Delivery Systems / methods*
Enzyme Inhibitors / pharmacology*,  therapeutic use
Humans
Signal Transduction / drug effects,  physiology
Tissue Survival / drug effects*,  physiology
Chemical
Reg. No./Substance:
0/Cyclins; 0/Enzyme Inhibitors; EC 2.7.11.22/Cyclin-Dependent Kinases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  New tools and concepts for modern organic synthesis.
Next Document:  The use of constitutively active GPCRs in drug discovery and functional genomics.